These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35094306)

  • 1. Hospitalization Rates in Patients with Heart Failure and Reduced Ejection Fraction Initiating Sacubitril/Valsartan or Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers: A Retrospective Cohort Study.
    Houchen E; Loefroth E; Schlienger R; Proudfoot C; Corda S; Saha S; Satwase SK; Studer R
    Cardiol Ther; 2022 Mar; 11(1):113-127. PubMed ID: 35094306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lower Hospitalization and Healthcare Costs With Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin-Receptor Blocker in a Retrospective Analysis of Patients With Heart Failure.
    Albert NM; Swindle JP; Buysman EK; Chang C
    J Am Heart Assoc; 2019 May; 8(9):e011089. PubMed ID: 31023122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction.
    Mohanty AF; Levitan EB; King JB; Dodson JA; Vardeny O; Cook J; Herrick JS; He T; Patterson OV; Alba PR; Russo PA; Obi EN; Choi ME; Fang JC; Bress AP
    J Am Heart Assoc; 2021 Oct; 10(20):e020474. PubMed ID: 34612065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction.
    Fu M; Pivodic A; Käck O; Costa-Scharplatz M; Dahlström U; Lund LH
    Clin Res Cardiol; 2023 Jan; 112(1):167-174. PubMed ID: 36443599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction and Advanced Chronic Kidney Disease: A Retrospective Multi-Institutional Study.
    Hsiao FC; Lin CP; Yu CC; Tung YC; Chu PH
    Front Cardiovasc Med; 2022; 9():794707. PubMed ID: 35360037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan.
    Mohanty AF; Levitan EB; Dodson JA; Vardeny O; King JB; LaFleur J; He T; Patterson OV; Alba PR; Russo PA; Choi ME; Bress AP
    Circ Heart Fail; 2019 Nov; 12(11):e005691. PubMed ID: 31718321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of sacubitril/valsartan versus angiotensin receptor blockers in patients with heart failure with preserved ejection fraction: A real-world study.
    Riaz M; Smith SM; Dietrich EA; Winchester DE; Guo J; Park H
    Am J Health Syst Pharm; 2024 Jul; 81(14):599-607. PubMed ID: 38427969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease.
    Lee WC; Liao TW; Chen TY; Fang HY; Fang YN; Chen HC; Lin YS; Chang SH; Chen MC
    Cardiovasc Drugs Ther; 2024 Jun; 38(3):505-515. PubMed ID: 36609948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
    Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure.
    Sun Y; Song S; Zhang Y; Mo W; Zhang X; Wang N; Xia Y; Tse G; Liu Y
    ESC Heart Fail; 2022 Feb; 9(1):667-675. PubMed ID: 34779134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF.
    Visco V; Radano I; Campanile A; Ravera A; Silverio A; Masarone D; Pacileo G; Correale M; Mazzeo P; Dattilo G; Giallauria F; Cuomo A; Mercurio V; Tocchetti CG; Di Pietro P; Carrizzo A; Citro R; Galasso G; Vecchione C; Ciccarelli M
    ESC Heart Fail; 2022 Oct; 9(5):2909-2917. PubMed ID: 35702942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world analysis of integration of sacubitril/valsartan into clinical practice in Saudi Arabia.
    Badreldin HA; Korayem GB; Alenazy BA; Aljohani MH; Alshaya OA; Al Sulaiman K; Alabdelmuhsin L; Alenazi H; Almutairi DM; Alanazi F; Alobathani SK; Alqannam GM; Almadani O; Aljuhani O; Hafiz A; Aljowaie G; Basha E; Alqahtani T; Alhussein M
    Medicine (Baltimore); 2023 Dec; 102(51):e36699. PubMed ID: 38134075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of Sacubitril/Valsartan in patients with acute heart failure: A multi-institution study.
    Chen DY; Chen CC; Tseng CN; Chen SW; Chang SH; Huang WK; Wen MS; Hsieh MJ; Hsieh IC
    EClinicalMedicine; 2021 Nov; 41():101149. PubMed ID: 34693232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal Outcomes in Patients with Systolic Heart Failure Treated With Sacubitril-Valsartan or Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker.
    Tan NY; Deng Y; Yao X; Sangaralingham LR; Shah ND; Rule AD; Burnett JC; Dunlay SM; Sangaralingham SJ
    Mayo Clin Proc Innov Qual Outcomes; 2021 Apr; 5(2):286-297. PubMed ID: 33997628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of sacubitril/valsartan versus aldosterone antagonists in heart failure with reduced ejection fraction: A retrospective cohort study.
    Riaz M; Smith SM; Dietrich EA; Pepine CJ; Park H
    Pharmacotherapy; 2021 Sep; 41(9):710-721. PubMed ID: 34170559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction.
    Tan NY; Sangaralingham LR; Sangaralingham SJ; Yao X; Shah ND; Dunlay SM
    JACC Heart Fail; 2020 Jan; 8(1):43-54. PubMed ID: 31838035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry.
    Zeymer U; Clark AL; Barrios V; Damy T; Drożdż J; Fonseca C; Lund LH; Kalus S; Ferber PC; Hussain RI; Koch C; Maggioni AP
    Eur Heart J Qual Care Clin Outcomes; 2022 Jun; 8(4):469-477. PubMed ID: 33725113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of heart failure pharmacotherapies in patients with heart failure with mildly reduced ejection fraction.
    Schupp T; Bertsch T; Reinhardt M; Abel N; Schmitt A; Lau F; Abumayyaleh M; Akin M; Weiß C; Weidner K; Behnes M; Akin I
    Eur J Prev Cardiol; 2024 Aug; 31(11):1347-1360. PubMed ID: 38513366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.